TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7579007

Group type: EXPERIMENTAL
Intervention: epalrestat (150 mg/day, 50 mg tid, po)
Number of subjects: 196

Group type: COMPARATOR
Intervention: placebo (9 mg/day, 3 mg tid, po)
Number of subjects: 196
Study: 1770154

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg daily
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg daily
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg daily
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Haloperidol (all doses)
Number of subjects: 73
Study: 7102708

Group type: EXPERIMENTAL
Intervention: Topical acyclovir
Number of subjects: 0
Study: 30690714

Group type: EXPERIMENTAL
Intervention: Immediate receipt of an individualized survivorship care plan (SCP)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Delayed receipt of an individualized survivorship care plan (SCP)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both arms combined (immediate and delayed SCP)
Number of subjects: 127
Study: 27884499

Group type: EXPERIMENTAL
Intervention: Open chain resisted band exercises (OC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Closed chain exercises (CC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Minimally loaded range of movement exercises (ROM)
Number of subjects: 120
Study: 26337820

Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low-glycemic-load (LGL) diet
Number of subjects: 27
Study: 23384734

Group type: EXPERIMENTAL
Intervention: Group P (pain assessment)
Number of subjects: 300
Study: 21386042

Group type: EXPERIMENTAL
Intervention: milieu language teaching (MLT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: broad target recasts (BTR)
Number of subjects: 57
Study: 19679384

Group type: COMPARATOR
Intervention: Traditional Chinese Medicine (TCM) recipe (Panax, 520 mg; Astragalus membranaceous Bunge, 520 mg; Masnetitum, 840 mg; Ostrea gigas Thumb, 470 mg; Thinleaf Milkwort Root Radix Polygalae, 450 mg; Os Draconis, 470 mg) administered as a diet supplement for 60 days.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was given).
Number of subjects: 14
Study: 17565930

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment administered twice daily for 5 days every 4 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no mupirocin treatment)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment
Number of subjects: 49
Study: 15633941

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 246
Study: 11452572

Group type: EXPERIMENTAL
Intervention: Acuband worn on the wrist
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acuband worn on the arm
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no Acuband)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acuband worn on the wrist or arm
Number of subjects: 25
Study: 9670693

Group type: EXPERIMENTAL
Intervention: Acupuncture treatments in addition to standard treatment (allopurinol, NSAIDs, glucocorticosteroids)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard treatment (allopurinol, NSAIDs, glucocorticosteroids)
Number of subjects: 38
Study: 7810077

Group type: EXPERIMENTAL
Intervention: Low-protein diet supplemented with ketoanalogs of essential amino acids and a low-phosphate drink from casein-free protein (Group I)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mixture of essential and non-essential amino acids of egg white (Group II)
Number of subjects: 36
Study: 2929157

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combination therapy (chemo and radiotherapy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Irradiation
Number of subjects: 53
Study: 31199555

Group type: EXPERIMENTAL
Intervention: Family-based Affect Management Intervention (FAMI)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Health Promotion Intervention (HPI)
Number of subjects: 47
Study: 29520926

Group type: EXPERIMENTAL
Intervention: Individual CBT
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Group CBT
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Guided parent-led CBT
Number of subjects: 1253
Study: 26948366

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with procarbazine, lomustine, vincristine (PCV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with temozolomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delaying radiotherapy and treatment with chemotherapy only
Number of subjects: 0
Study: 24449169

Group type: EXPERIMENTAL
Intervention: 60 Hz stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 130 Hz stimulation
Number of subjects: 0
Study: 23734703

Group type: EXPERIMENTAL
Intervention: Blood pressure measurement with care management support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure measurement with provider education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure measurement only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of all three interventions
Number of subjects: 0
Study: 20416080

Group type: EXPERIMENTAL
Intervention: CDA's CVD Toolkit (intervention arm)
Number of subjects: 800
Study: 18629552

Group type: EXPERIMENTAL
Intervention: Piezoosteotomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional saw and chisel osteotomy
Number of subjects: 90
Study: 15926947

Group type: EXPERIMENTAL
Intervention: Trichoderma harzianum exposure (approximately 350,000 spores/m3 for 6 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Penicillium chrysogenum exposure (approximately 600,000 spores/m3 for 6 min)
Number of subjects: 8
Study: 11934715

Group type: EXPERIMENTAL
Intervention: 0.05 ml/kg of 10 mM GSNO
Number of subjects: 20

Group type: COMPARATOR
Intervention: Phosphate buffered saline (placebo)
Number of subjects: 20
Study: 10656476

Group type: EXPERIMENTAL
Intervention: Self-administered food frequency questionnaire (FFQ) reviewed by a nutritionist
Number of subjects: 324

Group type: COMPARATOR
Intervention: Self-administered food frequency questionnaire (FFQ) without nutritionist review
Number of subjects: 324
Study: 8652950

Group type: EXPERIMENTAL
Intervention: IVIG or TMS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2328304

Group type: EXPERIMENTAL
Intervention: Sublingual dimenhydrinate (50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral dimenhydrinate (50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous dimenhydrinate (50 mg)
Number of subjects: 8
Study: 7370144

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Glycopyrrolate
Number of subjects: 56
Study: 31158718

Group type: EXPERIMENTAL
Intervention: MI+CBT (Motivational Interviewing + Cognitive Behavioral Therapy)
Number of subjects: 186

Group type: COMPARATOR
Intervention: SC+CBT (Supportive Counselling + Cognitive Behavioral Therapy)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: MI+CBT
Number of subjects: 186

Group type: COMPARATOR
Intervention: SC+CBT
Number of subjects: 186
Study: 28130918

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Anifrolumab 1,000 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 305
Study: 26210606

Group type: EXPERIMENTAL
Intervention: Priming dose of alcohol (.6 g/kg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Soft drink
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Bar-lab environment
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sterile lab environment
Number of subjects: 114
Study: 23766507

Group type: EXPERIMENTAL
Intervention: Simulated obstructive hypopnea (inspiration through a threshold load)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simulated obstructive apnea (Mueller maneuver)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: End‐expiratory central apnea
Number of subjects: 10
Study: 20937602

Group type: EXPERIMENTAL
Intervention: Intraperitoneal carboplatin in combination with intravenous weekly dose-dense paclitaxel
Number of subjects: 746

Group type: COMPARATOR
Intervention: Intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel
Number of subjects: 746
Study: 19448846

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for 16 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN) for 16 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 24
Study: 17146730

Group type: EXPERIMENTAL
Intervention: Indibulin 20 mg (fed condition)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indibulin 20 mg (fasted condition)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indibulin (dose escalation study)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indibulin 60 mg (recommended dose level)
Number of subjects: 14
Study: 15794406

Group type: EXPERIMENTAL
Intervention: Beclomethasone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 45
Study: 11354519

Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol (E2) administration (100 microg.d(‐1) x 3.5d -> 200 microg.d(‐1) x 3.5 d -> 300 microg.d(‐1) x 4.0 d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol (E2) administration
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study: 10958250

Group type: EXPERIMENTAL
Intervention: Clomipramine (oral doses of 10-40 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Propanteline (active placebo)
Number of subjects: 13
Study: 8291818

Group type: EXPERIMENTAL
Intervention: Practice guideline recommendation with concurrent reminders
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group (no concurrent reminders)
Number of subjects: 375
Study: 3354489

Group type: EXPERIMENTAL
Intervention: Zinc supplementation in American women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupplemented American and Egyptian women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium levels in milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium levels in milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc levels in milk
Number of subjects: 0
Study: 29739677

Group type: EXPERIMENTAL
Intervention: 15 g soy protein with 66 mg isoflavone (SPI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 15 g soy protein alone (SP)
Number of subjects: 200
Study: 27325551

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 25794517

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 2148

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2148
Study: 24304002

Group type: EXPERIMENTAL
Intervention: rFIXFc (recombinant factor IX Fc fusion protein) administered weekly (50 IU/kg)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: rFIXFc (recombinant factor IX Fc fusion protein) administered every 10 days (100 IU/kg)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: rFIXFc (recombinant factor IX Fc fusion protein) administered as needed for bleeding episodes (20 to 100 IU/kg)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: rFIXFc (recombinant factor IX Fc fusion protein) for perioperative treatment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: rFIXFc (recombinant factor IX Fc fusion protein)
Number of subjects: 123
Study: 21228266

Group type: EXPERIMENTAL
Intervention: Whey protein meal
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Casein protein meal
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Soy protein meal
Number of subjects: 23

Group type: COMPARATOR
Intervention: High-carbohydrate meal
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glucose meal
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Casein and Soy protein meals
Number of subjects: 23
Study: 17980878

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test before IVF cycle
Number of subjects: 280
Study: 17228986

Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention delivered during 4 weekly telephone sessions using audiotaped cognitive-behavioral strategies and a self-help manual.
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention
Number of subjects: 483

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 483
Study: 12846911

Group type: EXPERIMENTAL
Intervention: EpiDex (tissue-engineered autologous epidermal equivalent derived from outer root sheath keratinocytes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Split-thickness skin autografting
Number of subjects: 0
Study: 10632652

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.d.), clarithromycin (500 mg b.d.), amoxycillin (1 g b.d.) for 10 days (OAC)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg b.d.), clarithromycin (500 mg b.d.), amoxycillin (1 g b.d.) for 10 days (RAC)
Number of subjects: 104
Study: 9368169

Group type: EXPERIMENTAL
Intervention: HsS (elastoviscous hylan surgical shield, 0.45%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balanced salt solution
Number of subjects: 60
Study: 8238713

Group type: EXPERIMENTAL
Intervention: Standardized warm‐up, cool-down, and stretching exercises
Number of subjects: 421

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 421
Study: 3310827

Group type: EXPERIMENTAL
Intervention: 0.150 mg levonorgestrel plus 0.030 mg ethinyloestradiol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.150 mg desogestrel plus 0.030 mg ethinyloestradiol
Number of subjects: 20
Study: 29690966

Group type: EXPERIMENTAL
Intervention: Lower limb ergometer exercise for 8 weeks, 4 days/week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-trained control group
Number of subjects: 60
Study: 27042166

Group type: EXPERIMENTAL
Intervention: Thermogenic fat loss supplement (TFLS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 26609745

Group type: EXPERIMENTAL
Intervention: Great Users (17.2% of participants); high mean and level, no slope
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Good Users (32.8% of participants); moderate mean and level, no slope
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Low Users (22.7% of participants); low mean and level, negative slope
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Slow Decliners; moderate mean and level, negative slope, high variance
Number of subjects: 161
Study: 23533232

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate with increased protein diet
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both diet groups
Number of subjects: 111
Study: 20679593

Group type: EXPERIMENTAL
Intervention: Placebo with 75% expectation of receiving active medication
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Placebo with 25%, 50%, or 100% expectation of receiving active medication
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Expectation of clinical improvement
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Prior medication response
Number of subjects: 35
Study: 19086719

Group type: EXPERIMENTAL
Intervention: BIS index monitoring
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: AEP monitor
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard procedures (control group)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BIS index and AEP monitor
Number of subjects: 35
Study: 19034458

Group type: EXPERIMENTAL
Intervention: MRI-guided percutaneous nephrostomy (PCN) using a MRI-compatible drainage kit and Seldinger technique
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MRI-guided percutaneous nephrostomy (PCN) in dilated renal collection systems
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MRI-guided percutaneous nephrostomy (PCN)
Number of subjects: 8
Study: 15084996

Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Touch therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Remote intercessory prayer
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 150
Study: 11562517

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation programme (18 visits over 6 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 200
Study: 9784908

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8164818

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3280999

Group type: EXPERIMENTAL
Intervention: Physical therapy for 12 months (Group A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Infant stimulation for 6 months followed by physical therapy for 6 months (Group B)
Number of subjects: 48
Study: 31501052

Group type: EXPERIMENTAL
Intervention: Inhaled POL6014 (doses 80 to 320 mg in subjects with CF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled POL6014 (doses 20 to 960 mg in healthy volunteers)
Number of subjects: 0
Study: 31117835

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Matched controls without heart failure or ischemic heart disease
Number of subjects: 21
Study: 28377422

Group type: EXPERIMENTAL
Intervention: Offer of a free self-sampling kit online
Number of subjects: 11075

Group type: COMPARATOR
Intervention: Control group (invited to be screened in primary care settings)
Number of subjects: 11075
Study: 25170252

Group type: EXPERIMENTAL
Intervention: ER OC/APAP following a high-fat meal
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ER OC/APAP following a low-fat meal
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ER OC/APAP under fasted conditions
Number of subjects: 48
Study: 21958742

Group type: EXPERIMENTAL
Intervention: Typical angina
Number of subjects: 2319

Group type: EXPERIMENTAL
Intervention: Anginal equivalents
Number of subjects: 2319

Group type: EXPERIMENTAL
Intervention: Combination of symptoms
Number of subjects: 2319

Group type: EXPERIMENTAL
Intervention: Asymptomatic
Number of subjects: 2319

Group type: EXPERIMENTAL
Intervention: History of β-blocker use
Number of subjects: 2319

Group type: EXPERIMENTAL
Intervention: Previous percutaneous coronary intervention
Number of subjects: 2319
Study: 20002087

Group type: COMPARATOR
Intervention: Low-dose ritonavir (three oral doses of 100 mg over 24 h)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ALT-2074 (three oral doses of 80 mg over 24 h)
Number of subjects: 13
Study: 17284131

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75-225 mg/day)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 169
Study: 15113944

Group type: EXPERIMENTAL
Intervention: Test fat F (5 g/100 g long chain (n‐3) fatty acids)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Test fat F
Number of subjects: 16

Group type: COMPARATOR
Intervention: Test fat O
Number of subjects: 16
Study: 12575603

Group type: EXPERIMENTAL
Intervention: Liandai Capsule
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 9563534

Group type: EXPERIMENTAL
Intervention: Glutamine supplements (30 g/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no glutamine)
Number of subjects: 13
Study: 7889887

Group type: EXPERIMENTAL
Intervention: 6 mg boron/day supplement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2979275

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine and Ranitidine
Number of subjects: 0
Study: 30246749

Group type: EXPERIMENTAL
Intervention: Stainless steel crown restoration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unrestored contralateral teeth
Number of subjects: 60
Study: 27302483

Group type: EXPERIMENTAL
Intervention: Intraoperative ERCP
Number of subjects: 104

Group type: COMPARATOR
Intervention: LBDE
Number of subjects: 104
Study: 24962480

Group type: EXPERIMENTAL
Intervention: Oligonol (200 mg daily for 1 week)
Number of subjects: 19
Study: 22591964

Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nephrostomy tube
Number of subjects: 100
Study: 19940348

Group type: EXPERIMENTAL
Intervention: iButtons
Number of subjects: 8

Group type: COMPARATOR
Intervention: thermistors
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: iButtons and thermistors
Number of subjects: 8
Study: 18394829

Group type: EXPERIMENTAL
Intervention: 10 mg/day oral dehydroepiandrosterone (DHEA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 50 microg transdermal estradiol plus 100 mg/day oral micronized progesterone (HRT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: DHEA plus HRT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: DHEA, HRT, and DHEA plus HRT
Number of subjects: 32
Study: 16126372

Group type: EXPERIMENTAL
Intervention: 100 mg DHEA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 0
Study: 12546172

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 67

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 67
Study: 10659896

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 microg per vagina every 4 h as needed
Number of subjects: 91

Group type: COMPARATOR
Intervention: Oxytocin (intravenous)
Number of subjects: 91
Study: 7624736

Group type: EXPERIMENTAL
Intervention: 4 g n‐3 PUFAs daily for 6 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 0.65 g n‐3 PUFAs daily for 6 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 46